E. V. Kolokolova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
E. V. Kolokolova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Elena Viktorovna Surkova
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Irina Vladimirovna Glinkina
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - A. P. Galkina
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - A.M. Petrakovich
Siberian State Medical University, Tomsk, Russia
1 shared publication - Alexander Vladimirovich Shestakov
Siberian State Medical University, Ministry of Health of Russia
1 shared publication - Arina Alekseevna Mikhailova
Almazov National Medical Research Centre
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 273-279
Prevalence of geriatric syndromes and polypharmacy in elderly patients with type 2 diabetes mellitus: Cross-sectional study data
Introduction. Type 2 diabetes mellitus (T2DM) in the elderly is characterized by a high prevalence of geriatric syndromes (GS) and polypharmacy, which increases patient vulnerability. Therapy with sulfonylureas (SU) is associated with an increased risk of hypoglycemia, especially in older adults. Finding approaches to comprehensive outpatient support for these patients is relevant. Aim. To analyze the initial geriatric and clinical-metabolic status of a cohort of elderly patients with T2DM to substantiate an outpatient monitoring program aimed at correcting GS and optimizing therapy. Mat erials and methods. A cross-sectional study was conducted involving 40 T2DM patients (30 women, 10 men) aged ≥ 65 years receiving SU. All underwent comprehensive geriatric assessment (SPPB, dynamometry, Barthel and Lawton scales, MMSE, MoCA, GDS-15, Insomnia Severity Index), evaluation of clinical-metabolic parameters, fall risk, polypharmacy, and social activity. Results. The mean age was 72.3 ± 4.6 years, T2DM duration was 12 [8.0; 17.5] years, and HbA1c was 7.4 ± 1.1%. Polypharmacy was detected in 90% of patients, with a median number of drugs of 7 [5; 8]. Hypoglycemia history was reported by 45%, and 50% were unaware of its management. Prefrailty/frailty by SPPB was found in 40%, low muscle strength in 30%, falls in 30%, and home fall risk factors in 95%. Mild cognitive impairment by MoCA was detected in 42.5% (by MMSE – in 25%). Social activity was preserved in most (80%). Conclusions. A high prevalence of GS, polypharmacy, and poor awareness of hypoglycemia was revealed in elderly T2DM patients on SU therapy. The results justify the need to develop a comprehensive outpatient support program focused on deprescribing, fall prevention, and cognitive impairment management.
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 273-279
Open AccessPrevalence of geriatric syndromes and polypharmacy in elderly patients with type 2 diabetes mellitus: Cross-sectional study data
Introduction. Type 2 diabetes mellitus (T2DM) in the elderly is characterized by a high prevalence of geriatric syndromes (GS) and polypharmacy, which increases patient vulnerability. Therapy with sulfonylureas (SU) is associated with an increased risk of hypoglycemia, especially in older adults. Finding approaches to comprehensive outpatient support for these patients is relevant. Aim. To analyze the initial geriatric and clinical-metabolic status of a cohort of elderly patients with T2DM to substantiate an outpatient monitoring program aimed at correcting GS and optimizing therapy. Mat erials and methods. A cross-sectional study was conducted involving 40 T2DM patients (30 women, 10 men) aged ≥ 65 years receiving SU. All underwent comprehensive geriatric assessment (SPPB, dynamometry, Barthel and Lawton scales, MMSE, MoCA, GDS-15, Insomnia Severity Index), evaluation of clinical-metabolic parameters, fall risk, polypharmacy, and social activity. Results. The mean age was 72.3 ± 4.6 years, T2DM duration was 12 [8.0; 17.5] years, and HbA1c was 7.4 ± 1.1%. Polypharmacy was detected in 90% of patients, with a median number of drugs of 7 [5; 8]. Hypoglycemia history was reported by 45%, and 50% were unaware of its management. Prefrailty/frailty by SPPB was found in 40%, low muscle strength in 30%, falls in 30%, and home fall risk factors in 95%. Mild cognitive impairment by MoCA was detected in 42.5% (by MMSE – in 25%). Social activity was preserved in most (80%). Conclusions. A high prevalence of GS, polypharmacy, and poor awareness of hypoglycemia was revealed in elderly T2DM patients on SU therapy. The results justify the need to develop a comprehensive outpatient support program focused on deprescribing, fall prevention, and cognitive impairment management.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 148-160
Falls syndrome in elderly patients with diabetes mellitus: Risk factors, clinical significance, prevention
The number of patients with diabetes mellitus (DM) continues to increase steadily, particularly due to the rise in type 2 DM cases. This is associated not only with sedentary lifestyles, unbalanced diets, and the development of visceral obesity but also, significantly, with increased life expectancy, leading to a higher prevalence of DM among the elderly populations. Elderly patients constitute a heterogeneous group with numerous comorbidities and geriatric syndromes (GS), varying in levels of functional activity and cognitive function preservation. Besides a higher prevalence of chronic DM complications, which, alongside comorbidity, leads to polypharmacy, elderly DM patients face an increased risk of hypoglycemic events and the development of sarcopenia and frailty. One GS whose course is complicated by the presence of DM is fall syndrome. Factors increasing the risk of falls in elderly patients include behavioral, environmental, socioeconomic, and biological factors, encompassing both physiological and pathological conditions. Fall syndrome is the most common cause of injury among elderly and advanced-age patients, potentially reducing their quality of life and lifespan. However, this condition receives insufficient attention from both patients and healthcare providers. Consequently, when choosing management strategies for elderly patients, endocrinologists need to conduct a comprehensive geriatric assessment to identify factors increasing fall risk. This review presents the risk factors, diagnostic possibilities, and prevention strategies for falls in elderly patients with DM.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 148-160
Falls syndrome in elderly patients with diabetes mellitus: Risk factors, clinical significance, prevention
The number of patients with diabetes mellitus (DM) continues to increase steadily, particularly due to the rise in type 2 DM cases. This is associated not only with sedentary lifestyles, unbalanced diets, and the development of visceral obesity but also, significantly, with increased life expectancy, leading to a higher prevalence of DM among the elderly populations. Elderly patients constitute a heterogeneous group with numerous comorbidities and geriatric syndromes (GS), varying in levels of functional activity and cognitive function preservation. Besides a higher prevalence of chronic DM complications, which, alongside comorbidity, leads to polypharmacy, elderly DM patients face an increased risk of hypoglycemic events and the development of sarcopenia and frailty. One GS whose course is complicated by the presence of DM is fall syndrome. Factors increasing the risk of falls in elderly patients include behavioral, environmental, socioeconomic, and biological factors, encompassing both physiological and pathological conditions. Fall syndrome is the most common cause of injury among elderly and advanced-age patients, potentially reducing their quality of life and lifespan. However, this condition receives insufficient attention from both patients and healthcare providers. Consequently, when choosing management strategies for elderly patients, endocrinologists need to conduct a comprehensive geriatric assessment to identify factors increasing fall risk. This review presents the risk factors, diagnostic possibilities, and prevention strategies for falls in elderly patients with DM.
- Open Access
- 25 September 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (3) , 37-45
Disturbances of mineral metabolism and severe skeletal involvement in a patient with neurofibromatosis type 1
Neurofibromatosis type 1 (NF-1) is an autosomal dominant disorder caused by mutations in NF1 gene encoding neurofibromin protein. Mutations in this gene result in the absence of suppression of the Ras-MAPK pathway, which leads to increased cell proliferation and tumor development. In addition to the classic manifestations of neurofibromatosis (skin manifestations, tumors of the peripheral and cranial nerves, and scoliosis), patients may develop tumors of the endocrine glands: pheochromocytomas/paragangliomas and neuroendocrine tumors. Cases of NF-1 combined with acromegaly, adrenal tumors (including adrenocortical cancer), and primary hyperparathyroidism (PHPT) have been described. In addition, NF-1 is notable for the development of hypophosphatemic osteomalacia in rare cases.The article presents a description of a clinical case of a combination of PHPT in a patient with NF-1, hypophosphatemia that persisted after successful surgical treatment of PHPT, and severe skeletal involvement with multiple vertebral and non-vertebral fractures, which was assessed as a combination of severe osteoporosis and hypophosphatemic osteomalacia. During treatment with denosumab, teriparatide and alfacalcidol, increase of bone mineral density and normalization of phosphate levels were achieved. Nevertheless, the absence of consolidation of the femoral shaft fracture persists. Few cases of a combination of NF-1 simultaneously with PHPT and hypophosphatemic osteomalacia are described in the literature.
- 25 September 2024
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 27 (3) , 37-45
Open AccessDisturbances of mineral metabolism and severe skeletal involvement in a patient with neurofibromatosis type 1
Neurofibromatosis type 1 (NF-1) is an autosomal dominant disorder caused by mutations in NF1 gene encoding neurofibromin protein. Mutations in this gene result in the absence of suppression of the Ras-MAPK pathway, which leads to increased cell proliferation and tumor development. In addition to the classic manifestations of neurofibromatosis (skin manifestations, tumors of the peripheral and cranial nerves, and scoliosis), patients may develop tumors of the endocrine glands: pheochromocytomas/paragangliomas and neuroendocrine tumors. Cases of NF-1 combined with acromegaly, adrenal tumors (including adrenocortical cancer), and primary hyperparathyroidism (PHPT) have been described. In addition, NF-1 is notable for the development of hypophosphatemic osteomalacia in rare cases.The article presents a description of a clinical case of a combination of PHPT in a patient with NF-1, hypophosphatemia that persisted after successful surgical treatment of PHPT, and severe skeletal involvement with multiple vertebral and non-vertebral fractures, which was assessed as a combination of severe osteoporosis and hypophosphatemic osteomalacia. During treatment with denosumab, teriparatide and alfacalcidol, increase of bone mineral density and normalization of phosphate levels were achieved. Nevertheless, the absence of consolidation of the femoral shaft fracture persists. Few cases of a combination of NF-1 simultaneously with PHPT and hypophosphatemic osteomalacia are described in the literature.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (2) , 22-27
Prognostic markers of multiple sclerosis
Рассеянный склероз (РС) — хроническое аутоиммуное заболевание, имеющее высокую степень гетерогенности по своему течению и прогнозу. Более половины пациентов с РС не обсуждают долгосрочный прогноз с лечащим врачом. При этом большинство пациентов считают крайне важным получение персонализированной информации о течении РС для принятия решений в отношении планирования семьи, выбора профессии, лечебных вмешательств. Для определения прогноза в рутинной клинической практике используются клинические маркеры, но номинально они делятся на благоприятный и неблагоприятный факторы, что позволяет сделать обобщенное заключение о прогнозе РС. Преимущественно в научных целях используются нейровизуализационные и биологические маркеры, которые уже активно применяются в клинических исследованиях для определения влияния терапии на органические причины стойкой инвалидизации. В обзоре описаны исследования по изучению прогностической ценности ряда клинических, нейровизуализационных и биологических маркеров.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (2) , 22-27
Prognostic markers of multiple sclerosis
Рассеянный склероз (РС) — хроническое аутоиммуное заболевание, имеющее высокую степень гетерогенности по своему течению и прогнозу. Более половины пациентов с РС не обсуждают долгосрочный прогноз с лечащим врачом. При этом большинство пациентов считают крайне важным получение персонализированной информации о течении РС для принятия решений в отношении планирования семьи, выбора профессии, лечебных вмешательств. Для определения прогноза в рутинной клинической практике используются клинические маркеры, но номинально они делятся на благоприятный и неблагоприятный факторы, что позволяет сделать обобщенное заключение о прогнозе РС. Преимущественно в научных целях используются нейровизуализационные и биологические маркеры, которые уже активно применяются в клинических исследованиях для определения влияния терапии на органические причины стойкой инвалидизации. В обзоре описаны исследования по изучению прогностической ценности ряда клинических, нейровизуализационных и биологических маркеров.
- Open Access
- 15 May 2021
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 8 (2) , 8-22
Modern concepts of the molecular pathogenesis of thyroid cancer
Thyroid cancer remains the most common malignancy of the endocrine system worldwide. The indicators of its morbidity and mortality rates have been increasing rapidly over the last decades. Most cases of differentiated thyroid cancer (follicular and papillary histotypes) are clinically manifested by nodular goiter frequently combined with uncertain results of cytological diagnosis (categories III and IV according to the Bethesda (Bethesda System for Reporting Thyroid Cytopathology) classification). All of that makes it difficult to choose a proper tactic for patient treatment. It is known that the development, progression, invasion, and metastasis of cancer cells are regulated by a variety of molecular mechanisms. This review describes several molecular aspects of thyroid nodules oncogenesis, as well as its most promising diagnostic tumor markers. Following molecular pathways are described in particular: gene mutations, protein tumor markers, and epigenetic effects of micro-RNA, histones, as well as DNA methylation. The study of the pathogenesis of this disease has a prognostic value and contributes to the search for effective therapeutic and diagnostic methods and their improvement. That is why we also reviewed modern test panels aimed at preoperative differential diagnosis of thyroid nodules. Summarizing the results of world research on this topic allows us not only to expand the understanding of the fundamental processes of oncogenesis, but also to outline promising areas for future experimental research projects. All of that together will contribute to developing new prognostic, diagnostic and therapeutic technologies, and as a result, will improve the quality of medical care for patients with thyroid cancer.
- 15 May 2021
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 8 (2) , 8-22
Open AccessModern concepts of the molecular pathogenesis of thyroid cancer
Thyroid cancer remains the most common malignancy of the endocrine system worldwide. The indicators of its morbidity and mortality rates have been increasing rapidly over the last decades. Most cases of differentiated thyroid cancer (follicular and papillary histotypes) are clinically manifested by nodular goiter frequently combined with uncertain results of cytological diagnosis (categories III and IV according to the Bethesda (Bethesda System for Reporting Thyroid Cytopathology) classification). All of that makes it difficult to choose a proper tactic for patient treatment. It is known that the development, progression, invasion, and metastasis of cancer cells are regulated by a variety of molecular mechanisms. This review describes several molecular aspects of thyroid nodules oncogenesis, as well as its most promising diagnostic tumor markers. Following molecular pathways are described in particular: gene mutations, protein tumor markers, and epigenetic effects of micro-RNA, histones, as well as DNA methylation. The study of the pathogenesis of this disease has a prognostic value and contributes to the search for effective therapeutic and diagnostic methods and their improvement. That is why we also reviewed modern test panels aimed at preoperative differential diagnosis of thyroid nodules. Summarizing the results of world research on this topic allows us not only to expand the understanding of the fundamental processes of oncogenesis, but also to outline promising areas for future experimental research projects. All of that together will contribute to developing new prognostic, diagnostic and therapeutic technologies, and as a result, will improve the quality of medical care for patients with thyroid cancer.